The drug is specifically indicated for patients with decreased POMC, PCSK1, or leptin receptor (LEPR) or patients diagnosed with a rare genetic syndrome called Bardet-Biedl syndrome that presents with cognitive delays, short stature, and obesity in the pediatric population [76,77]. This evidence concerns the gene LEPR and obesity disorder.